Antioxidant and Antithrombotic Therapies for Diabetic Kidney Disease

Authors

  • Wenjun Yan Medical Center of the Graduate School, Nanchang University, Nanchang, China Author
  • Baoqin Zhou Medical Center of the Graduate School, Nanchang University, Nanchang, China Author
  • Yunfeng Shen Department of Endocrinology, Second Affiliated Hospital, Nanchang University, Nanchang, China Author
  • Gaosi Xu Department of Nephrology, Second Affiliated Hospital, Nanchang University, Nanchang, China Author

Abstract

With an increasing incidence, diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease and end-stage renal disease, and conventional therapies did not change this situation. This study intended to review and analyze the antioxidant and antithrombotic treatments of DKD for seeking novel therapeutic strategies. Relevant articles involved with antioxidant and antithrombotic treatments in DKD were retrieved and analyzed via systematic assessment. Meta-analysis showed that pancreatic kallikrein definitely reduced glycated hemoglobin in DKD patients (mean difference, 0.36%; 95% confidence interval, 0.08% to 0.63%; P = .01). Apart from the classic agents such as aspirin, novel drugs such as pancreatic kallikrein, sulodexide, and especially the traditional Chinese medicine including Tripterygium wilfordii and lumbrukinase, exert beneficial effects in DKD patients. Antioxidant and antithrombotic treatments are beneficial for DKD patients and represent promising therapeutic strategies in the future.

Downloads

Download data is not yet available.

Downloads

Published

2015-09-02

Issue

Section

REVIEW | Kidney Diseases

How to Cite

Antioxidant and Antithrombotic Therapies for Diabetic Kidney Disease. (2015). Iranian Journal of Kidney Diseases, 9(6), 413-420. https://www.ijkd.org/index.php/ijkd/article/view/2124